IQVIA™ Real-World Insights Bibliography

Comparison of electronic self-reported prescription medication use during pregnancy with the national prescription register in Denmark
Author(s): Maja Laursen 1, Christine E Hallgreen 2 3, Nancy Dreyer 4, Alison Bourke 5, Shahrul Mt-Isa 2 6, Stella Blackburn 5
Affiliations(s): 1The Danish Health Data Authority, Copenhagen, Denmark. 2School of Public Health, Imperial College London, London, UK. 3Copenhagen Center for Regulatory Science, Department of Pharmacy, SUND, University of Copenhagen, Copenhagen, Denmark. 4IQVIA Real-World and Analytic Solutions, Boston, Massachusetts. 5IQVIA Real-World and Analytic Solutions, London, UK. 6Biostatistics and Research Decision Sciences, MSD Research Laboratories, London, UK.
Publication(s):  Pharmacoepidemiol Drug Saf . 2020 Mar;29(3):328-336. doi: 10.1002/pds.4937. Epub 2019 Dec 6.
Document Type(s): Article,
Countries: Denmark, UK, USA,
Click here for the abstract
C:
Y:
Patient Registries & Real-World Study Methods, Pregnancy,
2020
  L:
A:
English
Epidemiological study, Methodology, Patient questionnaire, Real World Data,
  Add to report
 
 
Considerations when evaluating real-world data quality in the context of fitness for purpose
Author(s): Matthew W Reynolds 1, Alison Bourke 2, Nancy A Dreyer 3
Affiliations(s): 1Real World Solutions, IQVIA, Maryland, USA. 2Real World Solutions, IQVIA United Kingdom, UK. 3Real World Solutions, IQVIA, Massachusetts, USA.
Publication(s):  Pharmacoepidemiol Drug Saf . 2020 Oct;29(10):1316-1318. doi: 10.1002/pds.5010. Epub 2020 May 6.
Document Type(s): Article,
Countries: UK, USA,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes,
2020
  L:
A:
English
Real World Data, Real World Evidence,
  Add to report
 
 
Bridging the Gap Between RCTs and RWE Through Endpoint Selection
Author(s): Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10
Affiliations(s): 1Real World Evidence, Sanofi, Bridgewater, NJ, USA. 2AbbVie, Chicago, IL, USA. 3GSK, Philadelphia, PA, USA. 4IQVIA, Real-World Solutions, Cambridge, MA, USA. 5IQVIA, Real-World Solutions, London, UK. 6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland. 7Ferring Pharmaceuticals SA, St Prex, Switzerland. 8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden. 9Center for Observational Research, Amgen, Cambridge, UK. 10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com.
Publication(s):  Published online 2020 Jul 6. doi: 10.1007/s43441-020-00193-5
Document Type(s): Article,
Countries: Sweden, Switzerland, UK, USA,
Click here for the abstract
C:
Y:
Health status & patient reported outcomes,
2020
  L:
A:
English
Real World Data, Real World Evidence,
  Add to report
 
 
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
Author(s): Mafalda Ramos 1, Anastasia Ustyugova 2, Nikco Hau 3, Mark Lamotte 4
Affiliations(s): 1IQVIA Global HEOR, Porto Salvo 2740-266, Portugal. 2Boehringer Ingelheim International GmbH, TA CardioMetabolism Respiratory, Binger Str 173, Ingelheim am Rhein 55216, Germany. 3Boehringer Ingelheim Ltd, UK Market Access, Bracknell RG128YS, UK (at the time of the study). 4IQVIA, Global HEOR, Zaventem 1930, Belgium.
Publication(s):  Journal of Comparative Effectiveness Research 2020. https://doi.org/10.2217/cer-2020-0071
PMID: 32573253 DOI: 10.2217/cer-2020-0071
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Author(s): Mafalda Ramos 1, Michael H Cummings 2, Anastasia Ustyugova 3, Syed I Raza 4, Shamika U de Silva 4, Mark Lamotte 5
Affiliations(s): 1Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal. 2Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK. 3Boehringer Ingelheim International GmbH, 55216, Ingelheim Am Rhein, Germany. 4Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK. 5Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium. Mark.lamotte@iqvia.com.
Publication(s):  Diabetes Therapy 2020; 11(9), 2041-2055; https://doi.org/10.1007/s13300-020-00883-1.
PMID: 32700188 PMCID: PMC7434815 DOI: 10.1007/s13300-020-00883-1
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions
Author(s): Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4
Affiliations(s): 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com. 2Novo Nordisk A/S, Søborg, Denmark. 3IQVIA, Zaventem, Belgium. 4Health Economics and Outcomes Research Ltd, Cardiff, UK. 5IQVIA, Basel, Switzerland.
Publication(s):  Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30
Document Type(s): Article,
Countries: Belgium, Denmark, Switzerland, UK,
Click here for the abstract
C:
Y:
Health economics, Obesity,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
DOES INCLUDING ACUTE PANCREATITIS AS A COMPLICATION HAVE AN IMPACT ON COST-EFFECTIVENESS ANALYSES USING THE IQVIA CORE DIABETES MODEL?
Author(s): Monteiro S, Ramos M, Lamotte M
Affiliations(s): IQVIA HEOR Zaventem Brussels
Publication(s):  ISPOR US 2020 Orlando. Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB44.
Document Type(s): Poster,
Countries: UK,
C:
Y:
Diabetes, Health economics,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
IMPACT OF USING DIFFERENT TYPES OF HBA1C PROGRESSION IN THE IQVIA CORE DIABETES MODEL.
Author(s): Ramos M, Monteiro S, Lamotte M
Affiliations(s): IQVIA HEOR Zaventem Brussels
Publication(s):  ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52.
Document Type(s): Poster,
Countries: UK,
C:
Y:
Diabetes, Health economics,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Does Including EGFR Along to HBA1C As a Driver of Treatment Switch Changes Outcomes in Cost-Effectiveness Analyses in Type 2 Diabetes?
Author(s): Ramos M, Monteiro S, Lamotte M
Affiliations(s): IQVIA HEOR Zaventem Brussels
Publication(s):  ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 108179.
Document Type(s): Poster,
Countries: UK,
C:
Y:
Diabetes, Health economics,
2020
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Investigation of factors considered in the health technology assessment conducted by regulatory authority in eight countries
Author(s): Akira Yuasa 1, Naohiro Yonemoto 1, Sven Demiya 2, Chihiro Foellscher 2, Shunya Ikeda 3 (rwesheorj 2)
Affiliations(s): 1) Pfizer Japan Inc., Tokyo, Japan 2) IQVIA Solutions Japan, Tokyo, Japan 3) Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan
Publication(s):  ISPOR 2020 Conference
Document Type(s): Abstract,
Countries: Australia, Canada, France, Germany, Italy, Japan, Spain, UK,
Click here for the abstract
C:
Y:

2020
  L:
A:
English
  Add to report
 
 
First Page Previous Page  2 of 104 Next Page Last Page